Abstract:In EGFR-mutant NSCLC, MET amplification may cause resistance to EGFR tyrosine kinase inhibitors (TKIs). In a Phase Ib/II study in EGFR TKI-resistant patients with EGFR-mutant MET+ NSCLC, progression-free survival (PFS) and objective response rate (ORR) after ≥6 months of follow-up were improved with tepotinib (a highly selective MET TKI) plus gefitinib, compared with chemotherapy, particularly in patients with MET amplification. Here we present data at ≥18 months of follow-up. Asian patients with advanced, EGFR+, T790M-, MET+ NSCLC with resistance to prior EGFR TKIs were randomized to receive oral tepotinib 500 mg/day+gefitinib 250 mg/day or ≤6 cycles of cisplatin/carboplatin+pemetrexed chemotherapy±pemetrexed maintenance until confirmed progression, unacceptable toxicity, or withdrawal. Primary endpoint was investigator-assessed PFS. Secondary endpoints included ORR, overall survival (OS) and safety. Subgroup analyses were preplanned in MET IHC3+ and MET amplification populations (NCT01982955). Low recruitment halted full enrolment with 55 of 156 planned patients enrolled. As of 12-Dec-2018, median (range) duration of treatment with tepotinib+gefitinib was 21.4 (4.6, 110.9) weeks, with 3 patients still receiving treatment; and with pemetrexed was 18.0 (3.0, 60.4) weeks. 15 patients (62.5%) received ≥4 cisplatin/carboplatin cycles. Better outcomes were reported with tepotinib+gefitinib vs chemotherapy (Table), particularly in patients with MET IHC3+ (PFS: HR 0.35 [90% CI 0.17–0.74], OS: 0.32 [0.14–0.75]) or MET amplification (PFS: HR 0.13 [90% CI 0.04–0.43], OS: 0.08 [0.01–0.51]). Drug-related grade ≥3 adverse events (AEs) occurred in 17 (54.8%) patients receiving tepotinib+gefitinib and 12 (52.2%) patients receiving chemotherapy. Any-cause AEs leading to discontinuation occurred in 3 (9.7%) patients receiving tepotinib+gefitinib and 1 (4.3%) receiving chemotherapy. Dose reductions due to AEs were reported in 5 (16.1%) vs 4 (17.4%) patients. Tepotinib+gefitinib has durable antitumor activity in patients with EGFR-mutant NSCLC with MET IHC3+ or MET amplification and was generally well tolerated. MET amplification will be further explored as a biomarker for tepotinib.TableSummary of efficacy dataPopulationTepotinib + gefitinibChemotherapyHR/OR (90% CI)Overall MET+*Patients, n3124mPFS, months (90% CI)4.9 (3.9, 6.9)4.4 (4.2, 6.8)0.67 (0.35, 1.28)mOS, months (90% CI)17.3 (12.1, 37.3)18.7 (15.9, 20.7)0.67 (0.33, 1.37)ORR, n (%) [90% CI]14 (45.2) [29.7, 61.3]8 (33.3) [17.8, 52.1]1.99 (0.56, 6.87)MET IHC3+Patients, n1915mPFS, months (90% CI)8.3 (4.1, 21.2)4.4 (4.1, 6.8)0.35 (0.17, 0.74)mOS, months (90% CI)37.3 (24.2, 37.3)17.9 (12.0, 20.7)0.32 (0.14, 0.78)ORR, n (%) [90% CI]13 (68.4) [47.0, 85.3]5 (33.3) [14.2, 57.7]4.33 (1.03, 18.33)MET amplification†Patients, n127mPFS, months (90% CI)21.2 (8.3, NE)4.2 (1.4, 7.0)0.13 (0.04, 0.43)mOS, months (90% CI)37.3 (NE, NE)13.1 (3.3, NE)0.08 (0.01, 0.51)ORR, n (%) [90% CI]8 (66.7) [39.1, 87.7]3 (42.9) [12.9, 77.5]2.67 (0.37, 19.56)CEP-7, centromere protein 7; CI, confidence interval; EGFR, epidermal growth factor receptor; GCN, gene copy number; HR, hazard ratio; IHC, immunohistochemistry; IRC, independent review committee; ITT, intention to treat; MET, mesenchymal-epithelial transition factor; NE, not estimable; OR, odds ratio; ORR, objective response rate; OS, overall survival; PFS, progression-free survival All efficacy outcomes are investigator-assessed by RECIST v1.1. *IHC2+/IHC3+/gene amplification. †MET amplification is defined as GCN ≥5 and/or MET/CEP-7 ratio ≥2. 17 of 19 patients with MET amplification have MET overexpression (IHC3+). Open table in a new tab

Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations.

Gefitinib Plus Chemotherapy Versus Placebo Plus Chemotherapy in Egfr-Mutation- Positive Non-Small-Cell Lung Cancer after Progression on First-Line Gefitinib (impress): A Phase 3 Randomised Trial

Continuing EGFR-TKI in Combination with Super-Selected Arterial Infusion Chemotherapy Beyond RECIST PD for Patients with Advanced EGFR Positive Mutation Non-Small Cell Lung Cancer.

Gefitinib or Erlotinib Vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

T790M Mutation is Associated with Better Efficacy of Treatment Beyond Progression with EGFR-TKI in Advanced NSCLC Patients.

Continuation of Epidermal Growth Factor Tyrokine Kinase Inhibitor with or Without Chemotherapy Beyond Gradual Progression in Non-Small Cell Lung Cancer Patients.

[A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China].

Continuous Egfr Tyrosine Kinase Inhibitor Treatment with or Without Chemotherapy Beyond Gradual Progression in Non-Small Cell Lung Cancer Patients

EGFR-TKIs Plus Chemotherapy Demonstrated Superior Efficacy Than EGFR-TKIs Alone As First-Line Setting in Advanced NSCLC Patients with EGFR Mutation and BIM Deletion Polymorphism.

Intercalating and Maintenance Gefitinib Plus Chemotherapy Versus Chemotherapy Alone in Selected Advanced Non-Small Cell Lung Cancer with Unknown EGFR Status.

Mefatinib As First-Line Treatment of EGFR Sensitizing Mutation-Positive Non-Small-cell Lung Cancer: A Phase III Efficacy and Biomarker Study.

Concurrent Use of Metformin Enhances the Efficacy of EGFR-TKIs in Patients with Advanced EGFR-mutant Non-Small Cell Lung Cancer—an Option for Overcoming EGFR-TKI Resistance

Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study

Randomized controlled trial of chemotherapy plus geiftinib as ifrst-line treatment for patients with advancedEGFR mutation-positive lung adenocarcinoma

Intercalating and Maintenance Use of Gefitinib Plus Chemotherapy Versus Chemotherapy Alone in Selected Advanced Nsclc(Iscan,Ctong-1102): A Multicentre, Open-Label, Randomised, Phase 3 Study.

LBA2_PRGEFITINIB/CHEMOTHERAPY VS CHEMOTHERAPY IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION-POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC) AFTER PROGRESSION ON FIRST-LINE GEFITINIB: THE PHASE III, RANDOMISED IMPRESS STUDY

MA09.09 Long-Term Outcomes to Tepotinib Plus Gefitinib in Patients with EGFR-Mutant NSCLC and MET Dysregulation: 18-Month Follow-Up

EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study

Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study

P1.03-052 Comparing EGFR-TKI with EGFR-TKI Plus Chemotherapy As 1st Line Treatment in Advanced NSCLC Patients with Both Mutated EGFR and Bim Polymorphism

Gefitinib with or Without Transarterial Infusion Chemotherapy (cisplatin) for Large Nonsmall Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations.